STD Diagnostics Market – Growth, Trends, Impact of COVID-19,

New York, Aug. 04, 2022 (GLOBE NEWSWIRE) — announces the publication of the report “STD Diagnostics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” – https://www.reportlinker .com/p06311667/?utm_source=GNW

The COVID-19 pandemic is expected to have a significant impact on the diagnosis of sexually transmitted diseases. According to the Quest Diagnostics 2020 Health Trends, published by researchers at Penn State University in 2021, testing rates for diseases like gonorrhea and chlamydia have declined during the COVID-19 pandemic and weekly positivity rates have increased. Researchers found that testing and screening for sexually transmitted infections fell by 63% for men and 59% for women in the first months of the Covid-19 pandemic. The researchers also found that STI testing decreased by 40% between late February 2020 and early April 2020. So the decrease in testing, due to closures and lack of access to testing facilities, could have an impact in the STD diagnostics market.

Rising prevalence of STDs globally, increased patient awareness through education campaigns, and growing government initiatives are expected to drive the growth of the market. The report released by the World Health Organization in November 2021 states that more than 1.0 million sexually transmitted infections are contracted worldwide and most of them are asymptomatic. He also reported that each year there are approximately 374.0 million new infections with 1 in 4 sexually transmitted infections: gonorrhea, chlamydia, trichomoniasis and syphilis. Hence, such an increase in the prevalence and incidence rate of sexually transmitted diseases across the globe is expected to increase the demand for STD diagnostics, thereby propelling the growth of the market over the forecast period.

In addition, HIV continues to be a major public health problem worldwide. The purpose of screening is to identify individuals in an apparently healthy population who are at higher risk of having a health problem or condition so that early treatment or intervention can be provided and thereby reduce the incidence. and the death rate in the population. For example, in March 2022, the National Chlamydia Screening Program (NCSP) was organized in the UK. The main goal of the program is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time needed to test results and treatment and re-test after treatment. The program also shifts from prevention and control to harm reduction of untreated chlamydia infection by screening primarily women and girls. Additionally, in June 2022, the Centers for Disease Control and Prevention recommended and released guidelines for screening for sexually transmitted diseases to raise awareness of STD screening programs and the increasing burden of STDs worldwide. It has issued separate STD testing guidelines for each population group, such as women, pregnant women, men who have sex with women, men who have sex with men, transgender people and diverse genders and people living with HIV. Thus, the increase in the number of screening programs across the world is expected to increase the number of cases of sexually transmitted diseases, which in turn is expected to increase the demand for STD diagnostics. Hence, considerable market growth is expected over the forecast period.

Additionally, advancements in STD diagnosis and research and development in the development of new technologies are expected to fuel the growth of the market. Additionally, the market is witnessing a major shift from conventional technologies towards molecular diagnostics as STD diagnostics is the major breakthrough for the growth of the market.

Hence, all the above-mentioned factors are expected to drive the growth of the market studied.

Main market trends

The laboratory testing segment is expected to witness growth over the forecast period

Laboratory tests are the most common form of diagnosis of sexually transmitted diseases (STDs) across the world. As lab tests are reliable and offer high accuracy, their usage is high and people tend to trust lab tests more.

Abbott Laboratories offers an in vitro reverse transcription polymerase chain reaction (RT-PCR) test and an in vitro polymerase chain reaction (PCR) test for the detection of various sexually transmitted diseases such as gonorrhea and d others caused by Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalis. Likewise, Qiagen Inc. offers a wide range of diagnostic test kits, including STI tests for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with high clinical sensitivity and specificity, which are used to detect various sexually transmitted diseases.

Additionally, there have been continuous product launches in the area of ​​molecular diagnostics, which is one of the major factors responsible for the growth of the laboratory testing segment. More product launches allow labs to install instruments or equipment as needed.

For example, in May 2022, Qiagen Inc. launched NeuMoDxHSV 1/2 Quant Assay for the quantitation and differentiation of herpes simplex virus type 1 (HSV-1) and/or herpes simplex virus DNA. simplex type 2 (HSV-2) with European Commission approval. The emergence of this test allows the company to expand its product portfolio in laboratory testing, which ultimately contributes to the growth of the market through the innovative tests. In addition, in November 2021, Roche launched Cobas 5800 System, a real-time PCR molecular testing solution, a new molecular laboratory instrument, in countries accepting the CE mark. This launch helps the company expand its range of diagnostic products for various applications including STD diagnostics which is expected to contribute to the growth of the market studied.

Hence, due to the above-mentioned factors, the laboratory testing segment is expected to witness high growth during the forecast period.

North America Holds Largest Global STD Diagnostics Market Share

The global sexually transmitted disease diagnostics market is dominated by North America, owing to the high prevalence of STDs in the region. The United States is expected to be the largest market in the North American region due to the presence of a large number of diagnostic companies and higher awareness of the disease. In April 2022, a report released by the Centers for Disease Control and Prevention (CDC) titled “Sexually Transmitted Disease Surveillance, 2020” stated that STDs remain a significant public health problem in the country. According to the same source, Chlamydia trachomatis infection was the most common reportable sexually transmitted infection in the United States in 2020 with a total of 1,579,885 cases reported to the CDC. The CDC received reports of 677,769 different gonorrhea infections in 2020. 2020 saw 133,945 cases of syphilis across all phases, including 41,655 cases in the primary and secondary (P&S) stages of the disease, which are the most contagious. By increasing the demand for diagnostic processes for these diseases, the country’s market growth is therefore expected to expand with the prevalence of STDs.

Similarly, the CDC reported in May 2022 that 30,635 people in the United States and dependent territories acquired an HIV diagnosis in 2020. The report was titled “Diagnostics of HIV Infection in the United States and Dependent Areas, 2020 “. At the end of 2019, the number of Americans living with HIV was estimated at 1,189,700. Since early diagnosis is essential for the patient to live a long and healthy life, it is therefore expected that HIV prevalence will drive the request for diagnosis of diseases.

In August 2020, the United States Department of Health and Human Services developed a National Sexually Transmitted Infections Strategic Plan (STI Plan). Five high-level goals that frame the more specific targets of the STI Plan are presented alongside this vision. Prevention of new STIs is one of five related goals and objectives. In communities and populations most affected by STIs, increase access to high-quality, low-cost STI secondary prevention, including testing, care and treatment. Identify and treat STIs, including new and emerging disease threats, support the development and adoption of innovative STI diagnostic tools, therapeutic agents and other interventions. Thus, it is expected that such measures will accelerate the expansion of the market.

Additionally, in May 2021, a team led by Johns Hopkins University developed a wearable device and low-cost smartphone app to quickly diagnose gonorrhea and assess whether a specific strain will respond to first-line treatments. The innovation is an improvement over current testing methods used in hospitals and clinics, which can take up to a week to show results and during which individuals can unwittingly spread disease. Additionally, in March 2021, the National Alliance of State & Territorial AIDS Directors (NASTAD) partnered with Building Healthy Online Communities for a free home delivery program for HIV and STD testing kits called TakeMeHome.

Therefore, due to the above factors, the North America STD diagnostics market growth is expected to increase over the forecast period.

Competitive landscape

The STD diagnostics market is moderately competitive in nature. Major players in the STD diagnostics market are Abbott Laboratories, MedMira Inc, Qaigen Inc, Cepheid (Danaher Corporation), F. Hoffmann-La Roche AG, Diasorin SpA, bioMeriuex, Hologic, Inc, Bio-Rad Laboratories, Inc., among others. . These companies focus on partnership and product/technology licensing opportunities in the sexually transmitted disease diagnostics industry.

Additional benefits:

The Market Estimate (ME) sheet in Excel format
3 months of analyst support
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.



Comments are closed.